IRVINE, Calif., Aug. 02, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company’s Board of Directors. “Roshawn is an accomplished leader within the biopharma industry,” said Mike… Continue reading Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
